Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $33.4052W HIGH $109.00
Volume
281.18 K
Value Traded
36.55 M
Short % Float
17.35%
-5.87%Week
-44.05%1 Month
-41.7%3 Month
-47.07%6 Month
-75.8%5 Year
+18.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.41 B
EPS (TTM)
-4.60
P/E Ratio
-
Ent. Value
390.80 M
Total Shares
34.14 M
Float Shares
33.05 M
Insiders
3.21%
Institutions
104.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NKTR Catalyst Timeline
Dated clinical, regulatory and corporate events for Nektar Therapeutics
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nektar Therapeutics
904Total events
13Upcoming
203Tier-1 (high impact)
2010 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationRezpegaldesleukinPresentation
REZOLVE-AD maintenance period results presented at EADV Congress 2026
moderate-to-severe atopic dermatitissource ↗
●R&D DayRezpegaldesleukinPresentation
Nektar investor/analyst call to present 6-month off-treatment REZOLVE-AA data
severe-to-very-severe alopecia areatasource ↗
▲Subgroup AnalysisRezpegaldesleukinClinical Data
Subgroup analysis of REZOLVE-AA by alopecia areata episode duration
severe-to-very-severe alopecia areatasource ↗
▲Long Term DataRezpegaldesleukinClinical Data
Long-term durability data from REZOLVE-AA through 52 weeks and 6 months off treatment
severe-to-very-severe alopecia areatasource ↗
▲Trial InitiationRezpegaldesleukinTrial
Third Phase 3 study in global ZENITH AD program initiated
moderate-to-severe atopic dermatitissource ↗
▲Late-BreakerRezpegaldesleukinPresentation
Late breaking oral presentation of multi-omic biomarker sub-study data at EADV Congress 2026
atopic dermatitissource ↗
●AbstractRezpegaldesleukinPresentation
EADV 2026 accepted abstracts (including late-breakers) embargo lifts
▲Biomarker DataRezpegaldesleukinClinical Data
Biomarker sub-study shows early molecular responses as early as Week 2 correlated with Week 16 clinical response
atopic dermatitissource ↗
●Equity OfferingCorporate
Inducement grants of stock options and RSUs to eleven newly-hired employees
●Last Patient Last VisitRezpegaldesleukinTrial
REZOLVE-AA 6-month off-treatment follow-up period completed
severe-to-very-severe alopecia areatasource ↗
▲Full ResultsRezpegaldesleukinClinical Data
Publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results
moderate-to-severe atopic dermatitissource ↗
▲Primary Endpoint MetRezpegaldesleukinClinical Data
REZOLVE-AD met all primary and key secondary endpoints
moderate-to-severe atopic dermatitissource ↗
▲Trial InitiationRezpegaldesleukinTrial
Initiation of first two global registrational Phase 3 trials (ZENITH AD-1 and ZENITH AD-2) in ZENITH AD program
moderate-to-severe atopic dermatitissource ↗
▲Trial InitiationRezpegaldesleukinTrial
Initiation of first two Phase 3 ZENITH AD trials in atopic dermatitis
atopic dermatitissource ↗
◆Oral PresentationPresentation
Nektar Therapeutics to participate in 2026 Jefferies Global Healthcare Conference fireside chat
▲Trial InitiationRezpegaldesleukinTrial
Phase 3 program initiation in atopic dermatitis
atopic dermatitissource ↗
▼Equity OfferingCorporate
Closing of $373.8 million public offering including full exercise of underwriters' option
▼Equity OfferingCorporate
Proposed public offering of $250M common stock and pre-funded warrants
◆Oral PresentationRezpegaldesleukinPresentation
Investor call to discuss 52-week topline results from 16-week extension treatment period of REZOLVE-AA Phase 2b study
alopecia areatasource ↗
◆Topline ReadoutRezpegaldesleukinClinical Data
52-week topline results from 16-week extension treatment period of REZOLVE-AA Phase 2b study
alopecia areatasource ↗
▲Full ResultsRezpegaldesleukinClinical Data
52-week topline results from 16-week blinded treatment extension of REZOLVE-AA
severe-to-very-severe alopecia areatasource ↗
◆Trial InitiationRezpegaldesleukinTrial
Planned initiation of Phase 3 ZENITH-AD program
moderate-to-severe atopic dermatitissource ↗
▲Topline ReadoutRezpegaldesleukinClinical Data
Positive 52-week topline results from Phase 2b REZOLVE-AA study
alopecia areatasource ↗
◆End Of Phase 2 MeetingRezpegaldesleukinFDA Meeting
End-of-Phase 2 Meeting with FDA to align on Phase 3 program in alopecia areata
alopecia areatasource ↗
◆Additional DataRezpegaldesleukinClinical Data
Data from 16-week treatment extension of REZOLVE-AA
severe-to-very-severe alopecia areatasource ↗
▲Oral PresentationRezpegaldesleukinPresentation
Oral poster presentation of Phase 2b REZOLVE-AD efficacy and safety data at AAD 2026
moderate-to-severe atopic dermatitissource ↗
◆Poster PresentationRezpegaldesleukinPresentation
Oral poster presentation of Phase 2b REZOLVE-AD data at AAD 2026
atopic dermatitissource ↗
▲Late-BreakerRezpegaldesleukinPresentation
Late-breaking oral presentation of Phase 2b REZOLVE-AA 36-week data at AAD 2026
severe-to-very-severe alopecia areatasource ↗
◆Oral PresentationRezpegaldesleukinPresentation
Data from Phase 2b study of rezpegaldesleukin in alopecia areata accepted for late-breaking oral presentation at AAD 2026
alopecia areatasource ↗
●Oral PresentationRezpegaldesleukinPresentation
Presented data from Phase 2b REZOLVE-AD and REZOLVE-AA studies at 2026 American Academy of Dermatology Annual Meeting
atopic dermatitissource ↗
▲Partnership / LicenseNKTR-0165Corporate
Research collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165 in MS
multiple sclerosissource ↗
●IND Enabling CompleteNKTR-0165Preclinical
NKTR-0165 currently in IND-enabling studies
autoimmune and CNS disorderssource ↗
▼Equity OfferingCorporate
Closing of $460 million public offering including full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of upsized $400 million public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Proposed public offering of $300M common stock and pre-funded warrants
◆Topline ReadoutRezpegaldesleukinClinical Data
Topline results from 36-week maintenance period of REZOLVE-AD Phase 2b study
atopic dermatitissource ↗
●Oral PresentationRezpegaldesleukinPresentation
Conference call and webcast to discuss REZOLVE-AD maintenance data
moderate-to-severe atopic dermatitissource ↗
▲Full ResultsRezpegaldesleukinClinical Data
Positive 52-week maintenance data from REZOLVE-AD study
moderate-to-severe atopic dermatitissource ↗
▲Partnership / LicenseNKTR-0165Corporate
Established Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165 in multiple sclerosis
multiple sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How NKTR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | rezpegaldesleukin (REZPEG, NKTR-358) | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C57 / 100
Pipeline Score
$1.1B
Pipeline Value
Fair Value
Valuation Signal
8
Drugs Scored
0.8x
rNPV / MCap
Top 9%
Micro Cap(rank 60 of 658)
Percentile Rank
Nektar Therapeutics carries a moderate pipeline score (57/100), with $2.7B risk-adjusted pipeline value, led by Pegylated Irinotecan in Stage IV Non-small Cell Lung Cancer (NSCLC) (Phase 2), across $180B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every NKTR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rezpegaldesleukin Fast Track | alopecia areata | Phase 2b | 2026-10-01 | 75% at 4 months off treatment; 63% at six months off treatment; 19% of patients achieving SALT Score ≤10; 7% at the end of 52 weeks of treatment; 29% of patients at low dose achieved new SALT Score ≤20 responses; 31% of patients at high dose achieved new SALT Score ≤20 responsesRead More | New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zalevsky JonathanOfficer (Chief R&D Officer) | Sell | -186 9,570 held | $71.98 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NKTR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 4.3 % (-27.1 %) | 166.92 M | 2.39 M | -6.58% ( -168.52 K) |
NKTR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NKTR ranks across every disease it competes in
Competitive Position is a premium feature
See how NKTR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNKTR News
NKTR▼ -22.4%on this news· ran to -34% by day 3
/C O R R E C T I O N -- Nektar Therapeutics/
Nektar Therapeutics presented new data on rezpegaldesleukin at the EADV Congress 2026, demonstrating its long-term efficacy in treating alopecia areata and atopic dermatitis. The drug showed sustained response rates and hair regrowth in alopecia areata patients after treatment cessation. A third Phase 3 study for atopic dermatitis has been initiated, with another for alopecia areata set to begin in early 2027.
Read more →NKTR▼ -22.4%on this news· ran to -34% by day 3shared move
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
Nektar Therapeutics presented promising long-term data on rezpegaldesleukin at the EADV Congress 2026, highlighting its effectiveness in treating alopecia areata and atopic dermatitis. The Phase 2b studies showed sustained responses and deepening improvements in patients, with a significant percentage maintaining positive outcomes after treatment cessation. The company is advancing into Phase 3 trials for both indications.
Read more →NKTR▼ -22.4%on this news· ran to -34% by day 3shared move
/UPDATE -- Nektar Therapeutics/
Nektar Therapeutics presented new data on rezpegaldesleukin at the EADV Congress 2026, showcasing its long-term efficacy in treating alopecia areata and atopic dermatitis. The drug demonstrated sustained hair regrowth in alopecia areata patients even after treatment cessation. Additionally, Phase 3 studies for both conditions have been initiated, indicating a promising future for this novel therapy.
Read more →NKTRNew Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Nektar Therapeutics presented new biomarker data on rezpegaldesleukin at the EADV Congress 2026, showing early improvements in patients with atopic dermatitis. The study revealed significant molecular changes as early as Week 2, correlating with clinical responses at Week 16. This first-in-class therapy targets regulatory T cells to restore immune balance, addressing unmet needs in treatment.
Read more →NKTR▲ +5.9%on this news· ran to -18% by day 3shared move
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
Nektar Therapeutics announced that it will present new data from its Phase 2b studies of rezpegaldesleukin at the EADV Congress 2026. The presentations will include findings from the REZOLVE-AA study on alopecia areata and the REZOLVE-AD study on atopic dermatitis. An investor call is scheduled for October 1, 2026, to discuss the new data.
Read more →NKTR▲ +5.9%on this news· ran to -18% by day 3shared move
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics announced the grant of stock options and restricted stock units to eleven new employees under its 2025 Inducement Plan. This plan is designed to incentivize individuals who were not previously associated with the company. The stock options have an exercise price of $67.10 and will vest over four years, promoting long-term commitment.
Read more →NKTRNektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics announced positive results from the Phase 2b REZOLVE-AD study, which evaluated rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The study successfully met all primary and key secondary endpoints, indicating significant efficacy. This trial is notable for being the first large, placebo-controlled study to support T-reg modulation as a therapeutic approach.
Read more →NKTRNektar Therapeutics Announces Second Quarter 2026 Financial Results
Nektar Therapeutics reported its financial results for Q2 2026, highlighting a strong cash position of over $1 billion. The company initiated Phase 3 clinical trials for its lead program, rezpegaldesleukin, targeting atopic dermatitis and alopecia areata. Despite a net loss of $40.6 million, Nektar's financial outlook remains positive with a cash runway extending into 2028.
Read more →NKTRNektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the second quarter of 2026 on August 13, 2026. The announcement will be followed by a conference call hosted by CEO Howard Robin at 5:00 p.m. ET. The call will be accessible via a webcast and will include a review of the company's performance and future plans.
Read more →NKTR▲ +5.9%on this news
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics has launched two global Phase 3 trials for rezpegaldesleukin, a novel T-cell biologic aimed at treating moderate-to-severe atopic dermatitis. The trials, ZENITH AD-1 and ZENITH AD-2, will enroll treatment-naive patients, while ZENITH AD-3 will focus on treatment-experienced patients. Initial data is expected by mid-2028, with a BLA submission targeted for 2029.
Read more →NKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...
Nektar Therapeutics announced the granting of non-qualified stock options to five new employees under its 2025 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options, totaling 11,900 shares, have an exercise price equal to the closing stock price on the grant date and will vest over four years. Nektar is focused on developing treatments for autoimmune and chronic inflammatory diseases and is currently involved in several clinical trials for their lead product candidate, rezpegaldesleukin, among others.
Read more →NKTRNektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Nektar Therapeutics announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 2-4, 2026, in New York. The company's management will host a webcast on June 3, 2026, at 1:20 p.m. ET, which will also be available for replay. Nektar is focused on developing treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTRNektar Therapeutics Reports First Quarter 2026 Financial Results
Nektar Therapeutics reported its financial results for Q1 2026, highlighting a significant increase in cash and investments to $731.6 million. The company is preparing to advance its lead candidate, rezpegaldesleukin, into Phase 3 trials for atopic dermatitis and is seeing positive clinical responses in immune-mediated diseases. Despite a net loss of $44.9 million, the company remains well-positioned for future growth.
Read more →NKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of...
Nektar Therapeutics announced the granting of non-qualified stock options and restricted stock units to six new hires under its 2025 Inducement Plan. This plan, designed to attract individuals not previously associated with the company, complies with Nasdaq Listing Rule 5635(c)(4). The stock options are priced at the current market value and are structured to vest over four years, encouraging employee retention. This strategic move indicates Nektar's commitment to expanding its talent pool as it continues to advance its clinical-stage pipeline.
Read more →NKTRNektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
Nektar Therapeutics is set to announce its financial results for Q1 2026 on May 7, 2026. CEO Howard Robin will host a conference call at 5:00 p.m. ET to discuss the results. The call will be accessible via a webcast, which will be available for replay until June 7, 2026. Nektar is focused on developing treatments for autoimmune and chronic inflammatory diseases.
Read more →NKTRNektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics has successfully closed a public offering, raising $373.8 million by selling 4,062,500 shares at $92.00 each. This includes the full exercise of the underwriters' option to purchase additional shares. The offering was conducted under a shelf registration statement and managed by Jefferies, TD Cowen, and Piper Sandler.
Read more →NKTR▼ -5.1%on this newsshared move
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
Nektar Therapeutics has announced the pricing of an upsized public offering, raising $325 million by selling 3,532,609 shares at $92.00 each. The offering is set to close on April 23, 2026, and aims to fund general corporate purposes, including clinical trials for its lead candidate, rezpegaldesleukin. The company has also granted underwriters an option to purchase additional shares.
Read more →About Nektar Therapeutics
Headquarters455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
BIOPHARMAWATCH ELITE PLUS
Trade the next NKTR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime